Targeted agents for the systemic treatment of advanced hepatocellular carcinoma

Arun Azad, Fiona Chionh, Jonathan Cebon

Research output: Contribution to journalReview ArticleResearchpeer-review

2 Citations (Scopus)

Abstract

The prognosis for advanced hepatocellular carcinoma is poor and systemic therapy has historically been of limited benefit. However, novel targeted agents offer promise in improving patient outcomes. In a recent phase III study the oral multi-tyrosine kinase inhibitor sorafenib was demonstrated to have a survival advantage over a placebo in advanced hepatocellular carcinoma. Similar efficacy was demonstrated in a phase III trial limited to an Asian-Pacific group of patients. While these results are encouraging, it is vital to make further progress. In this review we examine current knowledge of targeted agents in advanced hepatocellular carcinoma. We also address some of the key issues that require exploration regarding the use of targeted agents in advanced hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)76-86
Number of pages11
JournalAsia-Pacific Journal of Clinical Oncology
Volume5
Issue number2
DOIs
Publication statusPublished - 2009
Externally publishedYes

Keywords

  • Angiogenesis inhibitor
  • Hepatocellular carcinoma
  • Receptor
  • SHARP
  • Sorafenib
  • Vascular endothelial growth factor

Cite this

@article{490155739d684902a11374748cd3b78c,
title = "Targeted agents for the systemic treatment of advanced hepatocellular carcinoma",
abstract = "The prognosis for advanced hepatocellular carcinoma is poor and systemic therapy has historically been of limited benefit. However, novel targeted agents offer promise in improving patient outcomes. In a recent phase III study the oral multi-tyrosine kinase inhibitor sorafenib was demonstrated to have a survival advantage over a placebo in advanced hepatocellular carcinoma. Similar efficacy was demonstrated in a phase III trial limited to an Asian-Pacific group of patients. While these results are encouraging, it is vital to make further progress. In this review we examine current knowledge of targeted agents in advanced hepatocellular carcinoma. We also address some of the key issues that require exploration regarding the use of targeted agents in advanced hepatocellular carcinoma.",
keywords = "Angiogenesis inhibitor, Hepatocellular carcinoma, Receptor, SHARP, Sorafenib, Vascular endothelial growth factor",
author = "Arun Azad and Fiona Chionh and Jonathan Cebon",
year = "2009",
doi = "10.1111/j.1743-7563.2009.01202.x",
language = "English",
volume = "5",
pages = "76--86",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "2",

}

Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. / Azad, Arun; Chionh, Fiona; Cebon, Jonathan.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 5, No. 2, 2009, p. 76-86.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Targeted agents for the systemic treatment of advanced hepatocellular carcinoma

AU - Azad, Arun

AU - Chionh, Fiona

AU - Cebon, Jonathan

PY - 2009

Y1 - 2009

N2 - The prognosis for advanced hepatocellular carcinoma is poor and systemic therapy has historically been of limited benefit. However, novel targeted agents offer promise in improving patient outcomes. In a recent phase III study the oral multi-tyrosine kinase inhibitor sorafenib was demonstrated to have a survival advantage over a placebo in advanced hepatocellular carcinoma. Similar efficacy was demonstrated in a phase III trial limited to an Asian-Pacific group of patients. While these results are encouraging, it is vital to make further progress. In this review we examine current knowledge of targeted agents in advanced hepatocellular carcinoma. We also address some of the key issues that require exploration regarding the use of targeted agents in advanced hepatocellular carcinoma.

AB - The prognosis for advanced hepatocellular carcinoma is poor and systemic therapy has historically been of limited benefit. However, novel targeted agents offer promise in improving patient outcomes. In a recent phase III study the oral multi-tyrosine kinase inhibitor sorafenib was demonstrated to have a survival advantage over a placebo in advanced hepatocellular carcinoma. Similar efficacy was demonstrated in a phase III trial limited to an Asian-Pacific group of patients. While these results are encouraging, it is vital to make further progress. In this review we examine current knowledge of targeted agents in advanced hepatocellular carcinoma. We also address some of the key issues that require exploration regarding the use of targeted agents in advanced hepatocellular carcinoma.

KW - Angiogenesis inhibitor

KW - Hepatocellular carcinoma

KW - Receptor

KW - SHARP

KW - Sorafenib

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=66849091820&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2009.01202.x

DO - 10.1111/j.1743-7563.2009.01202.x

M3 - Review Article

VL - 5

SP - 76

EP - 86

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 2

ER -